Bioequivalence Study of 0.25 mg Pramipexole Tablets

Phase 1, randomised, open-label trial of pramipexole in Parkinson's disease (PD) and restless legs syndrome (RLS) (2 arms), sponsored by Dexa Medica. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Observed Quantifiable Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 48 hours and 1 more. Started May 2015; status: completed.